Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions

1987/12/01 by Yoshihisa Kuwana, Yoshihiro Asakura, Naoko Utsunomiya +5 · 419 citations
Biochemistry, Genetics and Molecular Biology · Chemistry · Medicine · #Antibody #Antigen #Bacterial Genetics and Biotechnology #Biochemistry #Biology #CD8 #Chemistry #Chimeric gene #Fusion protein #Gene #Gene expression #Genetics #Immune system #Molecular biology #Monoclonal and Polyclonal Antibodies Research #RNA and protein synthesis mechanisms #Receptor #Recombinant DNA #T cell #T-cell receptor

paper · doi:10.1016/0006-291x(87)90502-x

published in Biochemical and Biophysical Research Communications 149(3), 960-968 (Elsevier BV)

openalex publication_date 1987/12/01 · openalex created_date 2016/06/24 · openalex updated_date 2026/07/26

Cited by

• Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo
• A guide to cancer immunotherapy: from T cell basic science to clinical practice
• Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. [europepmc]
• Design and development of therapies using chimeric antigen receptor-expressing T cells. [europepmc]
• Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. [europepmc]
• Engineered T cells: the promise and challenges of cancer immunotherapy. [europepmc]
• The Principles of Engineering Immune Cells to Treat Cancer. [europepmc]
• Global Manufacturing of CAR T Cell Therapy. [europepmc]
• Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. [europepmc]
• Chimeric Antigen Receptor Therapy. [europepmc]
• CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. [europepmc]
• Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. [europepmc]
• Adoptive cellular therapies: the current landscape. [europepmc]
• Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. [europepmc]
• Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects. [europepmc]
• Next-generation regulatory T cell therapy. [europepmc]
• Genetically engineered T cells for cancer immunotherapy. [europepmc]
• Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). [europepmc]
• A guide to cancer immunotherapy: from T cell basic science to clinical practice. [europepmc]
• Chimeric antigen receptor signaling: Functional consequences and design implications. [europepmc]
• CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? [europepmc]
• Immune Cells and Immunotherapy for Cardiac Injury and Repair. [europepmc]
• Cell Therapy: Types, Regulation, and Clinical Benefits. [europepmc]
• HLA-independent T cell receptors for targeting tumors with low antigen density. [europepmc]
• Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. [europepmc]
• From bench to bedside: the history and progress of CAR T cell therapy. [europepmc]
• CAR-T cell therapy for cancer: current challenges and future directions. [europepmc]